AI entity
Every one of those 1 sits in a single category, ai-models. Of the tracked stories, 1 of 1 also mention Bayer Aktiengesellschaft, the most common co-covered peer. They are better corroborated than the beat average, carrying 45 original sources each against 2.6 for the same window.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, ai-models. Of the tracked stories, 1 of 1 also mention Bayer Aktiengesellschaft, the most common co-covered peer. They are better corroborated than the beat average, carrying 45 original sources each against 2.6 for the same window. The 7 average consequence score is above the beat benchmark of 6.3 in the same window. We currently track 1 AI story that mention Genmab A/S, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 140 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab A/S. Shared-story counts are live from our verified record — not editorial picks.
Indian IT giants faced a significant sell-off as investors weighed the disruptive potential of generative AI on traditional outsourcing models. Meanwhile, the biotech sector experienced extreme volatility following high-stakes Phase 3 trial results from Compass Pathways and Ocular Therapeutix.
Genmab A/S is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
